Principles of immunogenicity using
Biacore™ T200 SPR system
June 11 at 9:00 a.m. EDT, 3:00 p.m. CET
The assessment of unwanted immunogenicity is a key parameter in the development process of biological protein drugs. Usually, ligand binding technologies such as ELISA are used for early immune responses, whereas SPR technology is utilized for the characterization of antibody isotypes, which may be important for the interpretation of the clinical consequences of unwanted immunogenicity.
Register to attend to learn when and how to use the SPR technology to obtain a deeper understanding of unwanted immunogenicity.